Two treatments show benefit in juvenile myasthenia gravis

(MedPage Today) – San Francisco – Two studies have shown the benefits of treating juvenile myasthenia gravis (MG) with newer medications. Interim results from the phase II/III ADAPT Jr study show that ifgartigimod (Fifegart), an approved drug…